Measured parameters | Arthritic animals (n = 154) | Non-arthritic animals (n = 24) | Mice with spondylitis (n = 80) | Mice without spondylitis (n = 47) |
---|---|---|---|---|
In vitro T-cell proliferation, SI | 2.96 ± 0.07 | 3.25 ± 0.13 | 3.00 ± 0.09 | 3.00 ± 0.14 |
In vitro IL-2 production (CTLL-2), SI | 2.67 ± 0.07 | 2.73 ± 0.15 | 2.68 ± 0.10 | 2.66 ± 0.11 |
In vitro IL-4 production, ng/106 cells | 2.65 ± 0.14 | 2.91 ± 0.34 | 2.79 ± 0.22 | 2.39 ± 0.18 |
In vitro IL-6 production, ng/106 cells | 1.83 ± 0.01 | 2.17 ± 0.33 | 1.88 ± 0.14 | 1.86 ± 0.19 |
In vitro IFN-γ production, ng/106 cells | 8.06 ± 0.28 | 8.50 ± 1.07 | 7.61 ± 0.37 | 9.56 ± 0.65a |
In vitro TNF-α production, ng/106 cells | 0.74 ± 0.01 | 0.77 ± 0.02 | 0.74 ± 0.01 | 0.75 ± 0.02 |
Serum IL-4, pg/mL | 15.29 ± 2.41 | 22.80 ± 5.92 | 15.52 ± 3.32 | 18.49 ± 4.46 |
Serum IL-6, pg/mL | 166.45 ± 20.21 | 106.18 ± 26.97 | 97.59 ± 14.94 | 65.05 ± 20.61 |
Serum IL-1β, pg/mL | 96.36 ± 11.55 | 41.70 ± 11.29 | 163.78 ± 27.72 | 143.10 ± 31.16 |
Serum IFN-γ, pg/mL | 26.14 ± 2.62 | 34.59 ± 6.27 | 25.05 ± 3.65 | 33.49 ± 4.55 |
IgG1 antibodies to human PG, mg/mL | 12.75 ± 0.57b | 8.30 ± 0.94 | 23.33 ± 0.78b | 8.85 ± 0.86 |
IgG2a antibodies to human PG, mg/mL | 1.36 ± 0.14a | 0.72 ± 0.29 | 1.44 ± 0.21a | 0.82 ± 0.17 |
IgG1 antibodies to PG, μg/mL | 172.55 ± 13.47b | 76.41 ± 10.56 | 174.99 ± 18.95a | 116.68 ± 17.7 |
IgG2a antibodies to PG, μg/mL | 68.01 ± 5.68b | 24.79 ± 6.76 | 72.10 ± 8.18b | 34.57 ± 6.16 |